Safety and Pharmacokinetics of Intranasally Administered Heparin Safety and Pharmacokinetics of Intranasally Administered Heparin
Purpose Intranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this research was to measure the safety and pharmacokinetics of clearance of intranasally administered UFH solution from the nasal cavity. Method...
Saved in:
| Published in | Pharmaceutical research Vol. 39; no. 3; pp. 541 - 551 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York
Springer US
01.03.2022
Springer Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Purpose
Intranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this research was to measure the safety and pharmacokinetics of clearance of intranasally administered UFH solution from the nasal cavity.
Methods
Double-blinded daily intranasal dosing in C57Bl6 mice with four doses (60 ng to 60 μg) of UFH was carried out for fourteen consecutive days, with both blood coagulation measurements and subject adverse event monitoring. The pharmacokinetics of fluorescent-labeled UFH clearance from the nasal cavity were measured in mice by
in vivo
imaging. Intranasal UFH at 2000 U/day solution with nasal spray device was tested for safety in a small number of healthy human subjects.
Results
UFH showed no evidence of toxicity in mice at any dose measured. No significant changes were observed in activated partial thromboplastin time (aPTT), platelet count, or frequency of minor irritant events over vehicle-only control. Human subjects showed no significant changes in aPTT time, international normalized ratio (INR), or platelet count over baseline measurements. No serious adverse events were observed.
In vivo
imaging in a mouse model showed a single phase clearance of UFH from the nasal cavity. After 12 h, 3.2% of the administered UFH remained in the nasal cavity, decaying to background levels by 48 h.
Conclusions
UFH showed no toxic effects for extended daily intranasal dosing in mice as well as humans. The clearance kinetics of intranasal heparin solution from the nasal cavity indicates potentially protective levels for up to 12 h after dosing. |
|---|---|
| AbstractList | Intranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this research was to measure the safety and pharmacokinetics of clearance of intranasally administered UFH solution from the nasal cavity.PURPOSEIntranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this research was to measure the safety and pharmacokinetics of clearance of intranasally administered UFH solution from the nasal cavity.Double-blinded daily intranasal dosing in C57Bl6 mice with four doses (60 ng to 60 μg) of UFH was carried out for fourteen consecutive days, with both blood coagulation measurements and subject adverse event monitoring. The pharmacokinetics of fluorescent-labeled UFH clearance from the nasal cavity were measured in mice by in vivo imaging. Intranasal UFH at 2000 U/day solution with nasal spray device was tested for safety in a small number of healthy human subjects.METHODSDouble-blinded daily intranasal dosing in C57Bl6 mice with four doses (60 ng to 60 μg) of UFH was carried out for fourteen consecutive days, with both blood coagulation measurements and subject adverse event monitoring. The pharmacokinetics of fluorescent-labeled UFH clearance from the nasal cavity were measured in mice by in vivo imaging. Intranasal UFH at 2000 U/day solution with nasal spray device was tested for safety in a small number of healthy human subjects.UFH showed no evidence of toxicity in mice at any dose measured. No significant changes were observed in activated partial thromboplastin time (aPTT), platelet count, or frequency of minor irritant events over vehicle-only control. Human subjects showed no significant changes in aPTT time, international normalized ratio (INR), or platelet count over baseline measurements. No serious adverse events were observed. In vivo imaging in a mouse model showed a single phase clearance of UFH from the nasal cavity. After 12 h, 3.2% of the administered UFH remained in the nasal cavity, decaying to background levels by 48 h.RESULTSUFH showed no evidence of toxicity in mice at any dose measured. No significant changes were observed in activated partial thromboplastin time (aPTT), platelet count, or frequency of minor irritant events over vehicle-only control. Human subjects showed no significant changes in aPTT time, international normalized ratio (INR), or platelet count over baseline measurements. No serious adverse events were observed. In vivo imaging in a mouse model showed a single phase clearance of UFH from the nasal cavity. After 12 h, 3.2% of the administered UFH remained in the nasal cavity, decaying to background levels by 48 h.UFH showed no toxic effects for extended daily intranasal dosing in mice as well as humans. The clearance kinetics of intranasal heparin solution from the nasal cavity indicates potentially protective levels for up to 12 h after dosing.CONCLUSIONSUFH showed no toxic effects for extended daily intranasal dosing in mice as well as humans. The clearance kinetics of intranasal heparin solution from the nasal cavity indicates potentially protective levels for up to 12 h after dosing. Purpose Intranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this research was to measure the safety and pharmacokinetics of clearance of intranasally administered UFH solution from the nasal cavity. Methods Double-blinded daily intranasal dosing in C57Bl6 mice with four doses (60 ng to 60 μg) of UFH was carried out for fourteen consecutive days, with both blood coagulation measurements and subject adverse event monitoring. The pharmacokinetics of fluorescent-labeled UFH clearance from the nasal cavity were measured in mice by in vivo imaging. Intranasal UFH at 2000 U/day solution with nasal spray device was tested for safety in a small number of healthy human subjects. Results UFH showed no evidence of toxicity in mice at any dose measured. No significant changes were observed in activated partial thromboplastin time (aPTT), platelet count, or frequency of minor irritant events over vehicle-only control. Human subjects showed no significant changes in aPTT time, international normalized ratio (INR), or platelet count over baseline measurements. No serious adverse events were observed. In vivo imaging in a mouse model showed a single phase clearance of UFH from the nasal cavity. After 12 h, 3.2% of the administered UFH remained in the nasal cavity, decaying to background levels by 48 h. Conclusions UFH showed no toxic effects for extended daily intranasal dosing in mice as well as humans. The clearance kinetics of intranasal heparin solution from the nasal cavity indicates potentially protective levels for up to 12 h after dosing. PurposeIntranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this research was to measure the safety and pharmacokinetics of clearance of intranasally administered UFH solution from the nasal cavity.MethodsDouble-blinded daily intranasal dosing in C57Bl6 mice with four doses (60 ng to 60 μg) of UFH was carried out for fourteen consecutive days, with both blood coagulation measurements and subject adverse event monitoring. The pharmacokinetics of fluorescent-labeled UFH clearance from the nasal cavity were measured in mice by in vivo imaging. Intranasal UFH at 2000 U/day solution with nasal spray device was tested for safety in a small number of healthy human subjects.ResultsUFH showed no evidence of toxicity in mice at any dose measured. No significant changes were observed in activated partial thromboplastin time (aPTT), platelet count, or frequency of minor irritant events over vehicle-only control. Human subjects showed no significant changes in aPTT time, international normalized ratio (INR), or platelet count over baseline measurements. No serious adverse events were observed. In vivo imaging in a mouse model showed a single phase clearance of UFH from the nasal cavity. After 12 h, 3.2% of the administered UFH remained in the nasal cavity, decaying to background levels by 48 h.ConclusionsUFH showed no toxic effects for extended daily intranasal dosing in mice as well as humans. The clearance kinetics of intranasal heparin solution from the nasal cavity indicates potentially protective levels for up to 12 h after dosing. Intranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this research was to measure the safety and pharmacokinetics of clearance of intranasally administered UFH solution from the nasal cavity. Double-blinded daily intranasal dosing in C57Bl6 mice with four doses (60 ng to 60 [mu]g) of UFH was carried out for fourteen consecutive days, with both blood coagulation measurements and subject adverse event monitoring. The pharmacokinetics of fluorescent-labeled UFH clearance from the nasal cavity were measured in mice by in vivo imaging. Intranasal UFH at 2000 U/day solution with nasal spray device was tested for safety in a small number of healthy human subjects. UFH showed no evidence of toxicity in mice at any dose measured. No significant changes were observed in activated partial thromboplastin time (aPTT), platelet count, or frequency of minor irritant events over vehicle-only control. Human subjects showed no significant changes in aPTT time, international normalized ratio (INR), or platelet count over baseline measurements. No serious adverse events were observed. In vivo imaging in a mouse model showed a single phase clearance of UFH from the nasal cavity. After 12 h, 3.2% of the administered UFH remained in the nasal cavity, decaying to background levels by 48 h. UFH showed no toxic effects for extended daily intranasal dosing in mice as well as humans. The clearance kinetics of intranasal heparin solution from the nasal cavity indicates potentially protective levels for up to 12 h after dosing. Purpose Intranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this research was to measure the safety and pharmacokinetics of clearance of intranasally administered UFH solution from the nasal cavity. Methods Double-blinded daily intranasal dosing in C57Bl6 mice with four doses (60 ng to 60 [mu]g) of UFH was carried out for fourteen consecutive days, with both blood coagulation measurements and subject adverse event monitoring. The pharmacokinetics of fluorescent-labeled UFH clearance from the nasal cavity were measured in mice by in vivo imaging. Intranasal UFH at 2000 U/day solution with nasal spray device was tested for safety in a small number of healthy human subjects. Results UFH showed no evidence of toxicity in mice at any dose measured. No significant changes were observed in activated partial thromboplastin time (aPTT), platelet count, or frequency of minor irritant events over vehicle-only control. Human subjects showed no significant changes in aPTT time, international normalized ratio (INR), or platelet count over baseline measurements. No serious adverse events were observed. In vivo imaging in a mouse model showed a single phase clearance of UFH from the nasal cavity. After 12 h, 3.2% of the administered UFH remained in the nasal cavity, decaying to background levels by 48 h. Conclusions UFH showed no toxic effects for extended daily intranasal dosing in mice as well as humans. The clearance kinetics of intranasal heparin solution from the nasal cavity indicates potentially protective levels for up to 12 h after dosing. Intranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this research was to measure the safety and pharmacokinetics of clearance of intranasally administered UFH solution from the nasal cavity. Double-blinded daily intranasal dosing in C57Bl6 mice with four doses (60 ng to 60 μg) of UFH was carried out for fourteen consecutive days, with both blood coagulation measurements and subject adverse event monitoring. The pharmacokinetics of fluorescent-labeled UFH clearance from the nasal cavity were measured in mice by in vivo imaging. Intranasal UFH at 2000 U/day solution with nasal spray device was tested for safety in a small number of healthy human subjects. UFH showed no evidence of toxicity in mice at any dose measured. No significant changes were observed in activated partial thromboplastin time (aPTT), platelet count, or frequency of minor irritant events over vehicle-only control. Human subjects showed no significant changes in aPTT time, international normalized ratio (INR), or platelet count over baseline measurements. No serious adverse events were observed. In vivo imaging in a mouse model showed a single phase clearance of UFH from the nasal cavity. After 12 h, 3.2% of the administered UFH remained in the nasal cavity, decaying to background levels by 48 h. UFH showed no toxic effects for extended daily intranasal dosing in mice as well as humans. The clearance kinetics of intranasal heparin solution from the nasal cavity indicates potentially protective levels for up to 12 h after dosing. |
| Audience | Academic |
| Author | Liu, Hao Pomin, Vitor H. Dwivedi, Rohini Bidwell, Gene L. Sharp, Joshua S. Cheng, Zhi Yu, Christian S. Gurley, Bill J. Harris, Hannah M. Fassero, Lauren A. Mitra, Dipanwita Kotha, Arun Kumar Tandon, Ritesh Harrison, Kerri A. Chougule, Mahavir Bhupal Boyet, Katherine L. Dahl, Eric Ashpole, Nicole M. |
| Author_xml | – sequence: 1 givenname: Hannah M. surname: Harris fullname: Harris, Hannah M. organization: Department of BioMolecular Sciences, University of Mississippi – sequence: 2 givenname: Katherine L. surname: Boyet fullname: Boyet, Katherine L. organization: Department of BioMolecular Sciences, University of Mississippi – sequence: 3 givenname: Hao surname: Liu fullname: Liu, Hao organization: Department of BioMolecular Sciences, University of Mississippi – sequence: 4 givenname: Rohini surname: Dwivedi fullname: Dwivedi, Rohini organization: Department of BioMolecular Sciences, University of Mississippi – sequence: 5 givenname: Nicole M. surname: Ashpole fullname: Ashpole, Nicole M. organization: Department of BioMolecular Sciences, University of Mississippi – sequence: 6 givenname: Ritesh surname: Tandon fullname: Tandon, Ritesh organization: Department of BioMolecular Sciences, University of Mississippi, Department of Microbiology and Immunology, University of Mississippi Medical Center, Department of Medicine, University of Mississippi Medical Center – sequence: 7 givenname: Gene L. surname: Bidwell fullname: Bidwell, Gene L. organization: Department of Neurology, University of Mississippi Medical Center – sequence: 8 givenname: Zhi surname: Cheng fullname: Cheng, Zhi organization: Department of BioMolecular Sciences, University of Mississippi – sequence: 9 givenname: Lauren A. surname: Fassero fullname: Fassero, Lauren A. organization: Department of Microbiology and Immunology, University of Mississippi Medical Center – sequence: 10 givenname: Christian S. surname: Yu fullname: Yu, Christian S. organization: Department of Microbiology and Immunology, University of Mississippi Medical Center – sequence: 11 givenname: Vitor H. surname: Pomin fullname: Pomin, Vitor H. organization: Department of BioMolecular Sciences, University of Mississippi – sequence: 12 givenname: Dipanwita surname: Mitra fullname: Mitra, Dipanwita organization: Department of Microbiology and Immunology, University of Mississippi Medical Center – sequence: 13 givenname: Kerri A. surname: Harrison fullname: Harrison, Kerri A. organization: National Center for Natural Products Research, University of Mississippi – sequence: 14 givenname: Eric surname: Dahl fullname: Dahl, Eric organization: National Center for Natural Products Research, University of Mississippi – sequence: 15 givenname: Bill J. surname: Gurley fullname: Gurley, Bill J. organization: National Center for Natural Products Research, University of Mississippi – sequence: 16 givenname: Arun Kumar surname: Kotha fullname: Kotha, Arun Kumar organization: Department of Pharmaceutics and Drug Delivery, University of Mississippi, Department of Pharmaceutical Sciences, Mercer University – sequence: 17 givenname: Mahavir Bhupal surname: Chougule fullname: Chougule, Mahavir Bhupal organization: Department of Pharmaceutics and Drug Delivery, University of Mississippi, Department of Pharmaceutical Sciences, Mercer University – sequence: 18 givenname: Joshua S. orcidid: 0000-0002-0115-0276 surname: Sharp fullname: Sharp, Joshua S. email: jsharp@olemiss.edu organization: Department of BioMolecular Sciences, University of Mississippi, Department of Chemistry and Biochemistry, University of Mississippi |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35237922$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl9rFDEUxYNU7Lb1C_ggA770Zeq9-TOZeRGXorZQqGAF30Imk9mmziRrMivstzfjttaWUvIQSH7nJOfee0D2fPCWkDcIJwgg3ydEaEQJlJbAsMGSvyALFJKVDfAfe2QBkvKylhz3yUFKNwBQY8NfkX0mKJMNpQvy8Zvu7bQttO-Kr9c6jtqEn87byZlUhL4491PUXic9DNti2Y3OuzTZaLvizK51dP6IvOz1kOzr2_2QfP_86er0rLy4_HJ-urwojeA4lYhatwaMpVIbxozQ0FTYAqJFMK1mjLU9bztpWAU9MEPrummhrri0gMDZIfmw811v2tF2xs4fG9Q6ulHHrQraqYc33l2rVfitsg_ISmaD41uDGH5tbJrU6JKxw6C9DZukaMUElxVKzOi7R-hN2ESf42WKSy6qWoh7aqUHq5zvQ37XzKZqKTPFatHMXidPUHl1dnQmN7R3-fyB4O3_Qf8lvOtZBuodYGJIKdpeGTfpyYU5txsUgprHQ-3GQ-XxUH_HQ81FpI-kd-7PithOlDLsVzbeV-MZ1R_nIMqV |
| CitedBy_id | crossref_primary_10_1016_j_jddst_2024_106266 crossref_primary_10_1016_j_cell_2025_01_012 crossref_primary_10_1055_s_0042_1749395 crossref_primary_10_1016_j_ijbiomac_2023_129032 crossref_primary_10_3390_v14122620 |
| Cites_doi | 10.1016/j.envint.2020.105730 10.1016/j.cell.2020.09.033 10.1074/jbc.M500911200 10.1038/s41586-020-2180-5 10.7150/ijbs.45472 10.1016/j.ijbiomac.2020.09.184 10.1038/nature02145 10.1006/viro.2002.1484 10.3389/fmolb.2020.628551 10.1128/JVI.75.18.8772-8780.2001 10.1016/j.cell.2020.03.045 10.1074/jbc.M006701200 10.1016/j.ijsu.2020.04.018 10.1016/j.ijbiomac.2021.04.148 10.1128/JVI.72.2.1438-1445.1998 10.1038/s41586-020-2179-y 10.1186/s13054-020-03120-0 10.1006/viro.1993.1192 10.3390/v11070596 10.1038/s41579-020-00459-7 10.1016/j.antiviral.2021.105077 10.1172/JCI200113799 10.1164/ajrccm.160.5.9809123 10.1016/j.carbpol.2021.117797 10.1016/j.scitotenv.2020.142575 10.1016/j.jbc.2021.101507 10.1002/path.1570 10.7554/eLife.61390 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. COPYRIGHT 2022 Springer Copyright Springer Nature B.V. Mar 2022 |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 – notice: 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. – notice: COPYRIGHT 2022 Springer – notice: Copyright Springer Nature B.V. Mar 2022 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TK 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1007/s11095-022-03191-4 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection PML(ProQuest Medical Library) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest One Academic Middle East (New) MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1573-904X |
| EndPage | 551 |
| ExternalDocumentID | PMC8890767 A747438591 35237922 10_1007_s11095_022_03191_4 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NIGMS NIH HHS grantid: P30 GM122733 – fundername: NIGMS NIH HHS grantid: P20 GM130460 |
| GroupedDBID | --- -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 123 199 1N0 1SB 2.D 203 28- 29O 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3SX 4.4 406 408 409 40D 40E 53G 5QI 5VS 67N 67Z 6NX 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAPKM AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYOK AAYQN AAYTO AAYZH ABAKF ABBBX ABBRH ABBXA ABDBE ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACZOJ ADBBV ADHHG ADHIR ADHKG ADIMF ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYPR ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFDZB AFEXP AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGQPQ AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHPBZ AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AYFIA AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN EN4 EPAXT ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO IHE IHR IJ- IKXTQ IMOTQ INH ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAK LLZTM LSO M1P M4Y MA- MK0 N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P PF0 PHGZT PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TEORI TSG TSK TSV TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK6 WK8 WOW YCJ YLTOR Z45 ZGI ZMTXR ZOVNA ~KM AAYXX ABFSG ACSTC AEZWR AFHIU AFOHR AHWEU AIXLP ATHPR CITATION PHGZM -4W -56 -5G -BR -EM 3V. ADINQ CGR CUY CVF ECM EIF GQ6 NPM Z5O Z7S Z7U Z7V Z7W Z7X Z81 Z82 Z83 Z84 Z87 Z88 Z8N Z8O Z8P Z8Q Z8R Z8V Z8W Z91 Z92 AEIIB PMFND 7TK 7XB 8FK ABRTQ K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c541t-11aabc0ce27ac33c5a0961b011e10cba333bf4bd7c360f03c2889b08647e01043 |
| IEDL.DBID | U2A |
| ISSN | 0724-8741 1573-904X |
| IngestDate | Thu Aug 21 18:41:27 EDT 2025 Fri Jul 11 07:59:10 EDT 2025 Sat Aug 16 17:12:48 EDT 2025 Tue Jun 17 21:27:09 EDT 2025 Tue Jun 10 20:38:13 EDT 2025 Wed Feb 19 02:25:11 EST 2025 Sun Jul 06 05:02:46 EDT 2025 Thu Apr 24 23:12:51 EDT 2025 Thu Apr 10 07:06:22 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | heparin intranasal delivery SARS-CoV-2 Covid-19 |
| Language | English |
| License | 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c541t-11aabc0ce27ac33c5a0961b011e10cba333bf4bd7c360f03c2889b08647e01043 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-0115-0276 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8890767 |
| PMID | 35237922 |
| PQID | 2647456855 |
| PQPubID | 37334 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8890767 proquest_miscellaneous_2635476171 proquest_journals_2647456855 gale_infotracmisc_A747438591 gale_infotracacademiconefile_A747438591 pubmed_primary_35237922 crossref_citationtrail_10_1007_s11095_022_03191_4 crossref_primary_10_1007_s11095_022_03191_4 springer_journals_10_1007_s11095_022_03191_4 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-03-01 |
| PublicationDateYYYYMMDD | 2022-03-01 |
| PublicationDate_xml | – month: 03 year: 2022 text: 2022-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States |
| PublicationSubtitle | An Official Journal of the American Association of Pharmaceutical Scientists |
| PublicationTitle | Pharmaceutical research |
| PublicationTitleAbbrev | Pharm Res |
| PublicationTitleAlternate | Pharm Res |
| PublicationYear | 2022 |
| Publisher | Springer US Springer Springer Nature B.V |
| Publisher_xml | – name: Springer US – name: Springer – name: Springer Nature B.V |
| References | J Lan (3191_CR24) 2020; 581 M Yu (3191_CR11) 2020; 7 M Tyagi (3191_CR17) 2001; 276 W Jin (3191_CR8) 2020; 163 W Li (3191_CR25) 2003; 426 L Morawska (3191_CR5) 2020; 139 3191_CR3 EA Gross (3191_CR30) 1982; 135 B Hu (3191_CR1) 2021; 19 3191_CR12 I Hamming (3191_CR7) 2004; 203 M Nicola (3191_CR2) 2020; 78 MC Dechecchi (3191_CR14) 2001; 75 L Yan (3191_CR9) 2021; 260 C Summerford (3191_CR15) 1998; 72 J Shang (3191_CR26) 2020; 581 KE Bendstrup (3191_CR29) 1999; 160 ZW Ye (3191_CR4) 2020; 16 W Ni (3191_CR21) 2020; 24 TM Clausen (3191_CR10) 2020; 183 M Zoepfl (3191_CR16) 2021; 190 Q Wang (3191_CR22) 2020; 181 3191_CR23 S Bose (3191_CR13) 2002; 298 Y Gupta (3191_CR27) 2021; 183 D Shukla (3191_CR20) 2001; 108 RR Vives (3191_CR18) 2005; 280 M Elsamadony (3191_CR6) 2021; 755 T Compton (3191_CR19) 1993; 193 G Paiardi (3191_CR28) 2021; 298 35194614 - medRxiv. 2022 Feb 17 |
| References_xml | – volume: 139 start-page: 105730 year: 2020 ident: 3191_CR5 publication-title: Environ Int doi: 10.1016/j.envint.2020.105730 – volume: 183 start-page: 1043 issue: 4 year: 2020 ident: 3191_CR10 publication-title: Cell. doi: 10.1016/j.cell.2020.09.033 – volume: 280 start-page: 21353 issue: 22 year: 2005 ident: 3191_CR18 publication-title: J Biol Chem doi: 10.1074/jbc.M500911200 – volume: 581 start-page: 215 issue: 7807 year: 2020 ident: 3191_CR24 publication-title: Nature. doi: 10.1038/s41586-020-2180-5 – volume: 16 start-page: 1686 issue: 10 year: 2020 ident: 3191_CR4 publication-title: Int J Biol Sci doi: 10.7150/ijbs.45472 – volume: 135 start-page: 83 issue: Pt 1 year: 1982 ident: 3191_CR30 publication-title: J Anat – volume: 163 start-page: 1649 year: 2020 ident: 3191_CR8 publication-title: Int J Biol Macromol doi: 10.1016/j.ijbiomac.2020.09.184 – volume: 426 start-page: 450 issue: 6965 year: 2003 ident: 3191_CR25 publication-title: Nature. doi: 10.1038/nature02145 – volume: 298 start-page: 73 issue: 1 year: 2002 ident: 3191_CR13 publication-title: Virology. doi: 10.1006/viro.2002.1484 – volume: 7 start-page: 628551 year: 2020 ident: 3191_CR11 publication-title: Front Mol Biosci doi: 10.3389/fmolb.2020.628551 – volume: 75 start-page: 8772 issue: 18 year: 2001 ident: 3191_CR14 publication-title: J Virol doi: 10.1128/JVI.75.18.8772-8780.2001 – volume: 181 start-page: 894 issue: 4 year: 2020 ident: 3191_CR22 publication-title: Cell. doi: 10.1016/j.cell.2020.03.045 – volume: 276 start-page: 3254 issue: 5 year: 2001 ident: 3191_CR17 publication-title: J Biol Chem doi: 10.1074/jbc.M006701200 – volume: 78 start-page: 185 year: 2020 ident: 3191_CR2 publication-title: Int J Surg doi: 10.1016/j.ijsu.2020.04.018 – volume: 183 start-page: 203 year: 2021 ident: 3191_CR27 publication-title: Int J Biol Macromol doi: 10.1016/j.ijbiomac.2021.04.148 – volume: 72 start-page: 1438 issue: 2 year: 1998 ident: 3191_CR15 publication-title: J Virol doi: 10.1128/JVI.72.2.1438-1445.1998 – volume: 581 start-page: 221 issue: 7807 year: 2020 ident: 3191_CR26 publication-title: Nature. doi: 10.1038/s41586-020-2179-y – volume: 24 start-page: 422 issue: 1 year: 2020 ident: 3191_CR21 publication-title: Crit Care doi: 10.1186/s13054-020-03120-0 – volume: 193 start-page: 834 issue: 2 year: 1993 ident: 3191_CR19 publication-title: Virology. doi: 10.1006/viro.1993.1192 – ident: 3191_CR3 – ident: 3191_CR12 doi: 10.3390/v11070596 – volume: 19 start-page: 141 issue: 3 year: 2021 ident: 3191_CR1 publication-title: Nat Rev Microbiol doi: 10.1038/s41579-020-00459-7 – volume: 190 start-page: 105077 year: 2021 ident: 3191_CR16 publication-title: Antivir Res doi: 10.1016/j.antiviral.2021.105077 – volume: 108 start-page: 503 issue: 4 year: 2001 ident: 3191_CR20 publication-title: J Clin Invest doi: 10.1172/JCI200113799 – volume: 160 start-page: 1653 issue: 5 Pt 1 year: 1999 ident: 3191_CR29 publication-title: Am J Respir Crit Care Med doi: 10.1164/ajrccm.160.5.9809123 – volume: 260 start-page: 117797 year: 2021 ident: 3191_CR9 publication-title: Carbohydr Polym doi: 10.1016/j.carbpol.2021.117797 – volume: 755 start-page: 142575 issue: Pt 1 year: 2021 ident: 3191_CR6 publication-title: Sci Total Environ doi: 10.1016/j.scitotenv.2020.142575 – volume: 298 start-page: 101507 issue: 2 year: 2021 ident: 3191_CR28 publication-title: J Biol Chem doi: 10.1016/j.jbc.2021.101507 – volume: 203 start-page: 631 issue: 2 year: 2004 ident: 3191_CR7 publication-title: J Pathol doi: 10.1002/path.1570 – ident: 3191_CR23 doi: 10.7554/eLife.61390 – reference: 35194614 - medRxiv. 2022 Feb 17;: |
| SSID | ssj0008194 |
| Score | 2.4271727 |
| Snippet | Purpose
Intranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this... Intranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this... Purpose Intranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this... PurposeIntranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 541 |
| SubjectTerms | Adverse events Animals Anticoagulants Anticoagulants - adverse effects Background levels Biochemistry Biomedical and Life Sciences Biomedical Engineering and Bioengineering Biomedicine Blood Blood coagulation COVID-19 Dosage Heparin Human subjects Humans Medical examination Medical Law Mice Mice, Inbred C57BL Nose Partial Thromboplastin Time Pharmacokinetics Pharmacology/Toxicology Pharmacy Platelets Polysaccharides Research Paper Safety Safety and security measures Sulfates Thromboplastin Toxicity |
| Subtitle | Safety and Pharmacokinetics of Intranasally Administered Heparin |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9QwDI9gvPCCNj4LGwoSGg9cRPPRpn3aJsR0IIEmsUn3FiVpqiFOvbG7Pdx_j92mLT2JPcdp09iO7dT-mZD3IvAgVI5pg6ViylclAzsvmSqsrD1IdeGxdvj7j3x-pb4tskW8cFvHtMr-TGwP6mrl8Y78ExhuDca-yLKTmz8Mu0bh39XYQuMheYTQZZjSpRdDwIXWroWP0kKB1isei2a60jmetrXJgmEdD8RRE8O0ezz_Y592cyd3fqC2dul8nzyJDiU96yTggDwIzVNyfNEhUm9n9HIssFrP6DG9GLGqt8_I6U9bh82W2qYaRn6D44nUdFXTr_j6xq7tcrmlPdAutvek84D9C5vn5Or8y-XnOYtNFZjPFN8wzq11PvVBaOul9JnFpi8O1Dzw1DsrpXS1cpX2Mk_rVHpRFKWDwEfpgLGbfEH2mlUTXhFac5uXNqQOvBaVVXUpfV54Bz4cuBU2Vwnh_Y4aHxHHsfHF0oxYycgFA1wwLRcMzPk4zLnp8Dbupf6AjDKojPBkb2NNAawPYa3MGQRLSiJEX0IOJ5SgRH463LPaRCVem1HkEvJuGMaZmJjWhNUd0shMaXAD4REvO8kY1g2-rdSlEAnRE5kZCBDaezrS_LpuIb5hz1Od64TMeukal_X_7Xh9_1e8IY9FJ_As5Ydkb3N7F47Apdq4t63e_AWl4RpY priority: 102 providerName: ProQuest |
| Title | Safety and Pharmacokinetics of Intranasally Administered Heparin |
| URI | https://link.springer.com/article/10.1007/s11095-022-03191-4 https://www.ncbi.nlm.nih.gov/pubmed/35237922 https://www.proquest.com/docview/2647456855 https://www.proquest.com/docview/2635476171 https://pubmed.ncbi.nlm.nih.gov/PMC8890767 |
| Volume | 39 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwEB6xuxcuiDdhl8pIaDnQSPEjcXKjRS0FRFXBViqnyHEdLaJKEe0e-u93Jk9SARKnHDx2LM-M5xvZ8xnglXDcCRXRtcFE-cquEx_jvPRVbGRu0apjS7XDn-fRbKk-rsJVXRS2a267N0eS5U7dFbvxoKwmFj5V3mDmcwJnIeXuaMVLMWr3X4xxJWmUFgp9XfG6VObPY_TC0fGm_FtUOr4xeXRsWkaj6X24V8NINqr0_gDuuOIhXC4qHurDkF11ZVW7Ibtki46h-vAI3n41udsfmCnWbcsPhJskzbY5-0C_L8zObDYH1tDr0qOebObo1cLiMSynk6t3M79-SsG3oeJ7n3NjMhtYJ7SxUtrQ0FMvGTq344HNjJQyy1W21lZGQR5IK-I4yTDdUdpRxiafwGmxLdwzYDk3UWJckCFWUeE6T6SNYpshckMwYSLlAW9WNLU1zzg9d7FJO4Zk0kKKWkhLLaTY503b52fFsvFP6dekqJRcEEe2pq4kwPkRmVU6whRJSSLm8-CiJ4muY_vNjarT2nV3KSJEjagyDkMPXrbN1JOuoxVue0MyMlQawR8O8bSyjHbeiGilToTwQPdsphUgQu9-S_H9uiT2xjUPdKQ9GDbW1U3r78vx_P_Ez-GuqBzAD_gFnO5_3bgXCKz22QBO9EoP4Gw0HY_n9H3_7dMEv-PJfPFlUHrZLZOsHK4 |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKe4BLxZtAASNBObAR8SNxckBQoNUubVcr2Eq9uY7jqIhVtrBbofwpfiMzebIr0VvPM3acmfHMOPF8Q8hL7pjjMsJrg4n0pc0SH-K88GVsRG7BqmOLtcPH42h4Ir-chqcb5E9bC4PXKlufWDnqbG7xG_lbCNwKgn0chu8vfvrYNQr_rrYtNGqzOHTlbziyLd6NPoN-X3F-sD_9NPSbrgK-DSVb-owZk9rAOq6MFcKGBruepGDnjgU2NUKINJdppqyIgjwQlsdxkkLmL5XDw4uAeW-QLQlUcARbH_fHk6-d74f4WgFWKS7Bz0jWlOnUxXosqKqhuY-VQ3ByWwmF6wHhn4i4fltz7ZdtFQkPbpPtJoWle7XN3SEbrrhLdic1BnY5oNO-pGsxoLt00qNjl_fIh28md8uSmiLrKD8g1UVuOs_pCB9fmIWZzUraQvtiQ1E6dNgxsbhPTq5F4A_IZjEv3CNCc2aixLgghTxJhlmeCBvFNoWsERIZE0mPsFai2jYY59hqY6Z7dGbUggYt6EoLGsa86cZc1AgfV3K_RkVp3P4wszVNFQOsD4G09B4cz6RAUECP7Kxwwra1q-RW1bpxGwvdG7lHXnRkHIlX4Qo3v0QeEUoFiSdM8bC2jG7dkE0LlXDuEbViMx0DgomvUorv5xWoOMg8UJHyyKC1rn5Z_xfH46vf4jm5OZweH-mj0fjwCbnFa-P3A7ZDNpe_Lt1TSOiW6bNmF1Fydt0b9y9B21fd |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkRAXxJuUAkaCcmCjxo_EyQFBRVntUqhWopX25jqOI1BX2cJuhfLX-HXM5ElWoreePXYcz4xnJpn5hpBX3DHHZYRpg4n0pc0SH-y88GVsRG5BqmOLtcNfj6PJqfw8D-db5E9bC4Nple2dWF3U2dLiN_J9MNwKjH0chvt5kxYxOxy_v_jpYwcp_NPattOoReTIlb8hfFu9mx4Cr19zPv508nHiNx0GfBtKtvYZMya1gXVcGSuEDQ12QElB5h0LbGqEEGku00xZEQV5ICyP4ySFKEAqh4GMgHVvkJtKhAx1TM27YA8tbQVdpbiEG0eypmCnLttjQVUXzX2sIYIYbmAUN03DP7ZxM29z4-dtZRPHd8mdxpmlB7X03SNbrrhP9mY1GnY5oid9cddqRPforMfJLh-QD99M7tYlNUXWjZyD04vUdJnTKT6-MCuzWJS0BfnF1qJ04rB3YvGQnF7LcT8i28WycE8IzZmJEuOCFDwmGWZ5ImwU2xT8R3BpTCQ9wtoT1bZBO8emGwvd4zQjFzRwQVdc0DDnbTfnosb6uJL6DTJK40UAK1vT1DPA_hBSSx9AoCYFwgN6ZHdACQpsh8Mtq3Vzgax0L-4eedkN40xMiivc8hJpRCgVuKCwxONaMrp9g18tVMK5R9RAZjoChBUfjhQ_vlfw4nDmgYqUR0atdPXb-v9x7Fz9Fi_ILVBX_WV6fPSU3Oa17PsB2yXb61-X7hl4duv0eaVClJxdt87-Ba09Wq0 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+Pharmacokinetics+of+Intranasally+Administered+Heparin&rft.jtitle=Pharmaceutical+research&rft.au=Harris%2C+Hannah+M&rft.au=Boyet%2C+Katherine+L&rft.au=Liu%2C+Hao&rft.au=Dwivedi%2C+Rohini&rft.date=2022-03-01&rft.issn=1573-904X&rft.eissn=1573-904X&rft.volume=39&rft.issue=3&rft.spage=541&rft_id=info:doi/10.1007%2Fs11095-022-03191-4&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0724-8741&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0724-8741&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0724-8741&client=summon |